CORONA Remedies Limited holds 22nd AGM, approves final dividend of ₹10 per share.
CORONA Remedies Limited held its 22nd AGM on July 9, 2026. Key decisions included approving the FY26 financial statements, declaring a final dividend of ₹10 per share, re-appointing Mr. Nirav Mehta, and appointing new statutory and secretarial auditors. Dr. Kirtikumar Mehta was re-appointed as Non-Executive Director and Chairman for 5 years.
The approval of financial statements and dividend declaration are significant for shareholders. Changes in auditors and director re-appointments are routine but important corporate actions.
The AGM passed several key resolutions, including the approval of financial statements and the declaration of a dividend, which are generally positive outcomes for shareholders. The re-appointment of directors and auditors also indicates stability.
CORONA Remedies Limited conducted its 22nd Annual General Meeting (AGM) on Thursday, July 09, 2026, via Video Conferencing / Other Audio Visual Means. The meeting commenced at 11:00 a.m. and concluded at 11:45 a.m.
During the AGM, several key resolutions were passed through remote e-voting. These included the adoption of Audited Financial Statements (Standalone and Consolidated) for the financial year ended March 31, 2026, and the Reports of the Board of Directors and Auditors. A final dividend of ₹ 10 per Equity Share (100%) for the Financial Year 2025-26 was declared.
Other approved resolutions pertained to the re-appointment of Mr. Nirav Mehta, who retires by rotation, and the appointment of M/s. Walker Chandiok & Co LLP as the Statutory Auditors, along with fixing their remuneration. The remuneration payable to the Cost Auditors for FY 2026-27 was ratified. Additionally, M/s. Dhara Patel, Company Secretary Firm, was appointed as the Secretarial Auditors. The meeting also approved the payment of commission to Non-Executive Directors and the remuneration for Dr. Kirtikumar Mehta as Non-Executive Director and Chairman for FY 2026-27. Furthermore, Dr. Kirtikumar Mehta was re-appointed as Non-Executive Director and Chairman for a term of 5 years.
The declaration of voting results, along with the Scrutinizer’s Report, will be disclosed separately to the Stock Exchanges. This information is also available on the company's website.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.